Posted by Michael Wonder on 15 Dec 2021
NICE finally accepts use of rare cancer therapy Poteligeo
15 December 2021 - NICE has reversed its earlier decision not to recommend the use of Kyowa Kirin’s Poteligeo (mogamulizumab).
The agency has published final guidance recommending the use of mogamulizumab for the treatment of adults in England and Wales with mycosis fungoides and Sézary syndrome – two sub-types of cutaneous T-cell lymphoma – who have received at least one prior systemic therapy.
